Biotech Stocks and Leveraged ETFs Plunge Led by Cue Biopharma Decline

Key Facts

1Cue Biopharma shares dropped 23.70% to $28.27 despite announcing positive Phase 2 results for its CUE-221 drug.

2bioAffinity Technologies shares declined by approximately 19% to $7.70.

3Leveraged ETFs tied to MSTR and AMD saw sharp movements driven by volatility in the underlying stocks.

Amid heightened volatility in clinical-stage companies, biotech stocks and single-stock leveraged ETFs experienced significant declines. Cue Biopharma shares dropped 23.70% to $28.27, despite the company announcing positive Phase 2 results for its CUE-221 drug candidate. According to reports, the downward momentum extended to bioAffinity Technologies, which saw a 19% decline to $7.70, while leveraged ETFs tied to MSTR and AMD reacted sharply to the volatile price action of their underlying assets.

The sector's performance highlights the risks of profit-taking following clinical updates and the mechanical pressure on leveraged instruments. Per market data, peer instrument BIAF stood at $9.43 as of the close on September 18, 2026, while MSTR closed at $153.92 on the same date. These movements underscore how momentum and daily-reset fund structures can amplify losses when clinical news fails to sustain a rally in the biotech space.

Investors should watch key technical levels as the market processes these declines; CUE was positioned at $37.05 at the close of September 18, 2026. While the upcoming economic calendar shows no direct sector catalysts, the recent day lows of $35.53 for CUE and $9.23 for BIAF may serve as immediate reference points for support. Monitoring the stability of these levels will be crucial for retail traders navigating the current bearish sentiment in small-cap biotech.